MD Biosciences Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:1991
Lead Investor(s):N/A

Estimated Revenue & Financials

  • MD Biosciences's estimated annual revenue is currently $9.1M per year.(?)
  • MD Biosciences's estimated revenue per employee is $155,000

Employee Data

  • MD Biosciences has 59 Employees.(?)
  • MD Biosciences grew their employee count by 9% last year.
  • MD Biosciences currently has 1 job openings.

MD Biosciences is a leading discovery and clinical-stage pharmaceutical and biotechnology company offering sophisticated research services, innovative bioproducts and advanced diagnostic capabilities. Our 25+ year history of unparalleled scientific expertise and proprietary methodologies in the inflammatory, oncology and neurology landscapes have positioned us at the forefront of the precision medicine movement. Our operations consist of the following business groups: MD Biosciences as a Preclinical Service Provider: Providing selective services in a fee-for-service model including in vitro screens, in vivo efficacy studies, determination of PK, pre-toxicity and mode of action. MD Biosciences as a CLIA Diagnostic Laboratory and Biomarker Development Facility: Services include biomarker validation, central laboratory functionality, molecular diagnostics, assay transfers, LDT/IVD/CDx development, flow cytometry and histopathology services. MD Biosciences as a Product Resource: Through the course of research, monoclonal antibodies, proteins and assays are developed at MD Biosciences laboratories. Manufactured products are provided for sale through dedicated offices, website (www.mdbioproducts.com) and representatives world wide. MD Biosciences as a Collaborative Drug Development Partner: Large and small pharma and biotech have accessed MD Biosciences expertise for the joint development of new drug candidates. MD Biosciences as an Investor: We invest jointly with Venture Capital companies, private investors, academia as well as other pharma development companies to advance promising programs further. Current pipeline includes novel compounds in the cross-section of pain and inflammation as well as a vectorized vaccine for canine osteocarcinoma. These programs are available for partnering for their next respective stages, whether clinical phase studies or pre-market regulatory approval as in the case of the veterinary vaccine.

keywords:N/A